Pedersen, Annie http://orcid.org/0000-0002-7498-7755
Stanne, Tara M.
Nilsson, Staffan
Klasson, Sofia
Rosengren, Lars
Holmegaard, Lukas
Jood, Katarina
Blennow, Kaj
Zetterberg, Henrik
Jern, Christina
Funding for this research was provided by:
Hjärt-Lungfonden (HLF-20160316)
Vetenskapsrådet (K2014-64X-14605-12-5)
Article History
Received: 22 March 2019
Revised: 23 June 2019
Accepted: 15 July 2019
First Online: 2 August 2019
Compliance with ethical standards
:
: Kaj Blennow has served as a consultant or at advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. Henrik Zetterberg has served at advisory boards of Roche Diagnostics, Wave, Samumed and CogRx and is a co-founder of Brain Biomarker Solutions in Gothenburg AB.
: The study was approved by the Ethics Committee of the University of Gothenburg.
: Written informed consent was obtained from all participants prior to enrollment. For participants who were unable to communicate, consent was obtained from their next-of-kin.